Repligen (RGEN)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$178.20-0.04%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
QuarterlyIQ Insights · RGEN
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 805.6 | 738.3 | 634.4 | 632.4 | 801.5 | 670.5 | 366.3 | 270.2 | 194.0 | 141.2 | 104.5 | 83.5 | 63.5 | 68.2 | 62.3 | 27.3 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 141.2 | 104.5 | 83.5 | 63.5 | 68.2 | 62.3 | 27.3 |
| Cost of Revenues | 374.9 | 352.0 | 359.8 | 353.9 | 345.8 | 279.3 | 156.6 | 119.1 | 86.5 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 312.0 | 290.5 | 263.4 | 218.6 | 215.8 | 183.9 | 119.6 | 95.6 | 65.7 | 51.5 | 30.9 | 24.7 | 17.2 | 12.7 | 13.2 | 8.0 |
| R&D Expenses | 57.2 | 54.2 | 43.2 | 42.7 | 43.9 | 34.3 | 20.2 | 19.5 | 15.8 | 8.7 | 7.4 | 5.7 | 5.6 | 7.3 | 10.5 | 12.5 |
| Operating Income | 18.2 | 55.2 | (35.1) | 47.7 | 224.7 | 167.2 | 69.8 | 36.1 | 26.0 | 14.0 | 16.0 | 13.8 | 10.7 | 22.9 | 11.1 | (0.4) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 21.5 | — | 2.0 | 1.2 | 11.3 | 10.8 | 9.3 | 6.7 | 6.4 | 3.8 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 |
| Other Non-Operating Income / Expenses | (10.0) | 7.2 | 8.1 | 9.0 | (5.5) | (13.7) | (10.6) | (9.9) | (4.6) | — | — | — | — | — | — | — |
| Asset Writedown | — | — | — | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | 8.2 | 62.4 | (27.0) | 56.7 | 219.1 | 153.5 | 59.2 | 26.2 | 21.4 | 7.2 | 11.7 | 13.4 | 11.1 | 23.0 | 11.3 | (0.0) |
| Income Tax Expense | 20.0 | 13.5 | (1.5) | 21.1 | 33.2 | 25.3 | (0.7) | 4.7 | 4.8 | (21.1) | 0.0 | 4.1 | 3.0 | 6.9 | (2.9) | (0.8) |
| Net Income | ||||||||||||||||
| Net Income | (11.8) | 48.9 | (25.5) | 35.6 | 186.0 | 128.3 | 59.9 | 21.4 | 16.6 | 28.4 | 11.7 | 9.3 | 8.2 | 16.1 | 14.2 | (0.0) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.21) | 0.87 | (0.46) | 0.64 | 3.35 | 2.33 | 1.14 | 0.44 | 0.38 | 0.74 | 0.35 | 0.28 | 0.25 | 0.51 | 0.46 | 0.00 |
| Diluted EPS | (0.21) | 0.86 | (0.46) | 0.63 | 3.24 | 2.24 | 1.11 | 0.44 | 0.37 | 0.72 | 0.34 | 0.28 | 0.25 | 0.50 | 0.45 | 0.00 |
| Revenue per Share | 14.24 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 56.6 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 48.3 | 43.8 | 38.2 | 0.0 | 32.9 | 32.5 | 31.7 | 30.9 | 30.8 |
| Diluted Weighted Avg Shares | 56.6 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 49.2 | 45.5 | 39.2 | 0.0 | 33.6 | 33.3 | 32.4 | 31.3 | 30.8 |
| Supplemental | ||||||||||||||||
| EBITDA | — | 133.9 | 34.6 | 116.3 | 275.7 | 205.7 | 96.9 | 57.0 | 41.8 | 24.5 | 21.3 | 18.4 | 14.7 | 26.0 | 14.6 | 1.3 |
| EBIT | 18.2 | 55.2 | (35.1) | 47.7 | 224.7 | 167.2 | 69.8 | 36.1 | 26.0 | 14.0 | 16.0 | 13.8 | 10.7 | 22.9 | 11.1 | (0.4) |
| Effective Tax Rate | 243.4% | — | — | 37.2% | 15.1% | 16.4% | -1.2% | 18.1% | 22.5% | -291.2% | 0.1% | 30.4% | 26.6% | 30.1% | -25.6% | 1918.6% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.